* 10. Limitation of Liability
    * 10.1 The parties agree that:
        * 10.1.1 subject to clauses 10.2, 10.3 and 10.4, UK Biobank’s maximum aggregate Liability under this MTA and/or in relation to the Approved Research Project shall be limited to the Access Charges paid or payable by the Applicant to UK Biobank (whether or not invoiced to the Applicant) in relation to the Approved Research Project; and
        * 10.1.2 subject to clauses 10.2, 10.3 and 10.5, the Applicant's maximum aggregate Liability under this MTA and/or in relation to the Approved Research Project shall be limited to the Access Charges paid or payable by the Applicant to UK Biobank (whether or not invoiced to the Applicant) in relation to the Approved Research Project.
    * 10.2 Notwithstanding clause 10.1 above, UK Biobank shall have no Liability to the Applicant and the Applicant shall have no Liability to UK Biobank for any:
        * 10.2.1 loss of profit (whether direct, indirect or consequential);
        * 10.2.2 loss of use, loss of revenue, loss of production or loss of business (in each case whether direct, indirect or consequential);
        * 10.2.3 loss of goodwill, loss of reputation or loss of opportunity (in each case whether direct, indirect or consequential);
        * 10.2.4 loss of anticipated savings or loss of margin (in each case whether direct, indirect or consequential);
        * 10.2.5 loss of use or value of any data or software (in each case whether direct, indirect or consequential); or
        * 10.2.6 indirect or consequential loss.
    * 10.3 Nothing in this MTA shall operate to exclude or limit any Liability which cannot legally be limited including but not limited to liability for:
        * 10.3.1 death or personal injury caused by negligence;
        * 10.3.2 for its fraud or fraudulent misrepresentation; and
        * 10.3.3 for any matter for which it is not permitted by law to exclude or limit, or to attempt to exclude or limit, its Liability.
    * 10.4 For the avoidance of doubt, UK Biobank shall have no responsibility or Liability (including but without limitation any product-related Liability) for any finding, product, test or treatment developed directly or indirectly by the Applicant using the Materials.
    * 10.5 Nothing in this MTA shall operate to exclude or limit the Applicant’s Liability to UK Biobank for any loss, damage, costs or expenses arising from:
        * 10.5.1 the Applicant’s failure to comply with clause 9 (Data Protection) and clauses 14.5 to 14.10 inclusive (Third-Party Processors);
        * 10.5.2 any breach of clause 2.2 or any circumstance in which the Applicant sub-licenses, distributes or otherwise shares the Materials (including any IPRs) with any unauthorised person or third party;
        * 10.5.3 any circumstance set out in clauses 4.5 and 4.7; and
        * 10.5.4 any Data Security Incident which is caused by the Applicant.
* 11. Term
    * 11.1 The term of this MTA shall commence on the Effective Date and shall end on the Completion Date unless terminated sooner in accordance with clause 12 or in accordance with law.
    * 11.2 The Term of this MTA may be extended by the Applicant (and with the agreement of UK Biobank) during the final year of the Approved Research Project in the following one (1) year increments:
        * 11.2.1 for a minimum of period of one (1) year;
        * 11.2.2 for a period of two (2) years; or
        * 11.2.3 for a maximum period of three (3) years;
    * on application to UK Biobank setting out (in reasonable detail) the reasons for the extension request and subject to the payment of the relevant further Access Charges.
    * 11.3 For the avoidance of doubt, the extensions set out in clause 11.2 above can be applied cumulatively (subject to applicable Access Charges) so that, for example, an extension of 3 years may be granted to take the Approved Research Project duration from 3 years to 6 years, and this may then be extended by a further 3 years to 9 years and so on.
* 12. Termination and consequences of termination
    * 12.1 UK Biobank shall be entitled to terminate this MTA immediately by written notice to the Applicant if the Applicant:
        * 12.1.1 commits any breach of a material provision of this MTA or a material breach of this MTA, and, in the case of a breach capable of remedy, fails to remedy the same within 10 days after receipt of a written notice giving particulars of the breach and requiring it to be remedied; or
        * 12.1.2 ceases, is likely to cease, or threatens to cease carrying on business or suffers an Insolvency Event, or is subject to a serious, adverse regulatory finding.
    * 12.2 Upon expiry of the MTA pursuant to clause 11.1 above or termination of this MTA by UK Biobank pursuant to clause 12.1 or in accordance with law:
        * 12.2.1 the grant of rights and all licences to the Applicant under this MTA shall be automatically terminated; and
        * 12.2.2 the Applicant shall destroy the Materials or otherwise render them permanently inaccessible and confirm in writing to access@ukbiobank.ac.uk that this has been done. For the avoidance of doubt, the Applicant shall not be required to destroy Results Data or Other Data subject to the provisions of this MTA being complied with.
    * 12.3 Without prejudice to the foregoing and to any other rights or remedies that UK Biobank may have, UK Biobank may take the following steps if there is a breach that entitles UK Biobank to terminate this MTA under clause 12.1:
        * 12.3.1 it may prohibit the Applicant PI, Applicant Researchers and any other researchers from the Applicant Institution from accessing any further Materials from within the UK Biobank resource for an indefinite period of time; and/or
        * 12.3.2 it may elect to inform the relevant personnel within the defaulting Applicant Institution, funders of the defaulting Applicant PI and/or governing or other relevant regulatory bodies.
    * 12.4 Notwithstanding termination of this MTA for any reason, the provisions of clauses 2, 3, 4, 5, 7, 8, 9, 10, 12, 13, 14, 16 and 17 shall continue in force in accordance with their respective terms.
    * 12.5 Termination or expiry of this MTA shall not affect the rights and obligations of the parties accrued at the date or termination or expiry.